title: Topically applied heparins for the treatment of vascular disorders : a comprehensive review.
abstract: Effective treatment of peripheral vascular disorders is important not only for resolution of local symptoms but also for preventing the development of systemic conditions such as deep vein thrombosis. Topical heparins are widely used in Europe for the prevention and treatment of local symptoms associated with peripheral vascular disorders. This comprehensive review of the literature evaluated the efficacy and safety of topically applied heparins for the treatment of vascular disorders. A total of 1055 patients participated in a total of 20 studies that compared topical heparin formulations with placebo, no treatment, subcutaneous heparin or with each other in the treatment of superficial thrombophlebitis or venous insufficiency. Heparin gel 1000 IU/g (Lioton) 1000 gel, Menaven) 1000 gel) was more effective than placebo in reducing the signs and symptoms of superficial thrombophlebitis. Liposomal heparin gel 2400 IU/g (LipoHep Forte) was as effective as subcutaneous low-molecular-weight heparin at relieving local symptoms of superficial venous thrombosis. In head-to-head studies comparing different topical heparin formulations, all preparations appeared effective but heparin gel 1000 IU/g was superior to a heparinoid mucopolysaccharide cream (Hirudoid) in patients with vascular disorders in terms of resolving spontaneous pain, induced pain, oedema and heaviness in the limb. Another study demonstrated the superiority of heparin gel 1000 IU/g compared with a gel formulation containing heparin 100 IU/g, aescinate and essential phospholipids (Essaven), for symptom resolution. All treatments were generally well tolerated, with a relatively low incidence of local skin events. In summary, topical heparin preparations may be useful for relieving the signs and symptoms of vascular disorders while improving microcirculation. There is some evidence to suggest that heparin gel 1000 IU/g may be more effective than other topical preparations in treating these conditions, possibly because of the relatively high heparin levels in this formulation. This remains to be tested in well controlled, adequately powered clinical trials.
authors.affiliation: UO Medicina Riabilitativa a Indirizzo Vascolare, Presidio Ospedaliero di Passirana, Garbagnate Milanese, Milan, Italy. cesarevecchio@fastwebnet.it
authors.forename: Cesare
authors.initials: C
authors.lastname: Vecchio
authors.forename: Anna
authors.initials: A
authors.lastname: Frisinghelli
mesh_terms: D000287:Administration, Topical; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D013924:Thrombophlebitis / Q000188:drug therapy*; D016896:Treatment Outcome; D014689:Venous Insufficiency / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants; D006493:Heparin
references.citation: Angiology. 2001 Dec;52 Suppl 3:S57-62
references.pmid: 11775651
references.citation: Angiology. 2001 Dec;52 Suppl 3:S23-7
references.pmid: 11775645
references.citation: Ann Chir Gynaecol. 1990;79(2):92-6
references.pmid: 1696799
references.citation: Hemodial Int. 2006 Oct;10 Suppl 2:S2-4
references.pmid: 17022746
references.citation: Haematologica. 2005 May;90(5):672-7
references.pmid: 15921382
references.citation: Eur Heart J. 2006 Dec;27(23):2858-65
references.pmid: 17098762
references.citation: Fortschr Med. 1977 Jun 16;95(23):1557-60
references.pmid: 69596
references.citation: Blood Coagul Fibrinolysis. 1992 Dec;3(6):827-8
references.pmid: 1283344
references.citation: Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004982
references.pmid: 17443561
references.citation: Br Med J. 1979 Feb 17;1(6161):454-5
references.pmid: 427406
references.citation: Lancet. 2000 Jun 3;355(9219):1936-42
references.pmid: 10859038
references.citation: Ann Intern Med. 2007 Feb 6;146(3):211-22
references.pmid: 17261856
references.citation: Arch Surg. 2006 Aug;141(8):790-7; discussion 797-9
references.pmid: 16924087
references.citation: Minerva Cardioangiol. 1987 Apr;35(4):195-203
references.pmid: 3601108
references.citation: Angiology. 2001 Dec;52 Suppl 3:S49-55
references.pmid: 11775649
references.citation: Arch Immunol Ther Exp (Warsz). 1976;24(6):807-10
references.pmid: 828036
references.citation: Lik Sprava. 1999 Jan-Feb;(1):122-4
references.pmid: 10424022
references.citation: Indian J Physiol Pharmacol. 1988 Jul-Sep;32(3):223-5
references.pmid: 3058605
references.citation: Eur J Clin Pharmacol. 1999 Feb;54(12):917-21
references.pmid: 10192751
references.citation: Klin Khir. 1999;(6):5-6
references.pmid: 10483173
references.citation: Angiology. 2001 Dec;52 Suppl 3:S11-6
references.pmid: 11775643
references.citation: Br Med J. 1975 Sep 13;3(5984):614-6
references.pmid: 51664
references.citation: Angiology. 2001 Dec;52 Suppl 3:S29-34
references.pmid: 11775646
references.citation: Angiology. 2005 Jan-Feb;56(1):9-17
references.pmid: 15678251
references.citation: Angiology. 2001 Dec;52 Suppl 3:S43-8
references.pmid: 11775648
references.citation: J Natl Cancer Inst. 1993 Nov 17;85(22):1865-6
references.pmid: 8230268
references.citation: Angiology. 2001 Dec;52 Suppl 3:S17-21
references.pmid: 11775644
references.citation: Angiology. 2001 Dec;52 Suppl 3:S69-72
references.pmid: 11775653
references.citation: Angiology. 2001 Dec;52 Suppl 3:S35-41
references.pmid: 11775647